Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

Summary

The purpose of this trial is to assess the efficacy and tolerability of memantine (anti-excitotoxic, neuroprotective treatment currently used in Alzheimer's disease \[AD\]) in frontotemporal dementia patients after a one-year treatment.

Conditions

• Dementia

Interventions

DRUG

memantine

Sponsors & Collaborators

• Nantes University Hospital

  lead OTHER

Principal Investigators

• Martine Vercelletto, MD · Centre de la Mémoire, Clinique Neurologique CHU Nord Nantes 44093 France; [email protected]

• Lucette Lacomblez, MD · Federation de Neurologie AP-HP Paris 75 013 France; [email protected]

• Bruno Dubois, MD · Centre du Langage et de Neuropsychologie AP-HP Paris 75013 France; [email protected]

• Anne Sophie Rigaud, MD · Hôpital Broca, Paris 75 France; [email protected]

• Jean-Francois Dartigues, MD · Hôpital Pellegrin Bordeaux 33 076 France; [email protected]

• Sophie Auriacombe, MD · Hôpital Pellegrin Bordeaux 33 076 France ; [email protected]

• Philippe Couratier, MD · Hôpital Dupuytren, Limoges 87000 France; [email protected]

• Jacques Touchon, MD · Hôpital Gui de Chaulliac, Montpellier 34 295 France; [email protected]

• Matthieu Ceccaldi, MD · Hôpital de la Timone Marseille 13 005 France; [email protected]

• Mira Didic, MD · Hôpital de la Timone Marseille 13005 France; [email protected]

• Serge Bakchine, MD · Hôpital Maison Blanche, Reims 51 092 France; [email protected]

• Bernard-Francois Michel, MD · Hôpital Sainte Marguerite, 13009 France; [email protected]

• Catherine Thomas-Anterion, MD · Hôpital Bellevue Saint Etienne, 42 000 France; [email protected]

• Bernard Laurent, MD · Hôpital Bellevue Saint Etienne 42 000 France; [email protected]

• Francois Sellal, MD · Hôpital Civil Strasbourg 67000 France; [email protected]

• Serge Belliard, MD · Hôpital Pontchaillou Rennes 35 000, France; [email protected]

• Herve Allain, MD · Service de Pharmacologie, CHU de Rennes 35 000 France ; [email protected]

• Michele Puel, MD · Hôpital Purpan, Toulouse 31059 France; [email protected]

• Jean-Francois Demonet, MD · Clinique Neurologique CHU Purpan Toulouse 31059 France; [email protected]

• Marie Sarazin, MD · Centre du Langage et de la Mémoire, Hôpital de la Salpétriére AP-HP Paris 75013 France

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

45 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-09-30

Countries

• France

Study Locations